VIP
A neuropeptide that does three unrelated jobs — anti-inflammatory, bronchodilator and immune regulator — and is researched for all of them.
Vasoactive Intestinal Peptide, a neuropeptide with anti-inflammatory, bronchodilatory and immunomodulatory effects.
- Also known as
- Vasoactive intestinal peptide; aviptadil
- Class
- 28-amino-acid neuropeptide
- Evidence
- Early human studies
- FDA
- Not approved
- WADA 2026
- Not named
Concentrations · 1 vial
from R 5505mg selected — in stock and shipping now.
About VIP
Vasoactive Intestinal Peptide was first identified in the gut, which is where its name comes from, but it is found throughout the body and functions as a neuropeptide and a hormone at once. Its receptors sit on immune cells, in the lungs, in the gut and in the brain, which is why its research profile is so much broader than most compounds here.
The research interests that bring people to it are usually the anti-inflammatory and immunoregulatory ones, particularly in chronic inflammatory conditions. The bronchodilatory and pulmonary interest is a distinct strand of the same literature. It is one of the more specialised products in the catalogue and it tends to be bought for a specific reason rather than as part of a general protocol.
Specifications
Evidence level: Early human studies · Human trials as aviptadil gave mixed results; a large 2023 trial found no benefit.
- Structure
- Vasoactive intestinal peptide: a 28-amino-acid neuropeptide of the secretin-glucagon family
What it’s researched for
Research context, not medical advice. Everything we sell is supplied for research purposes.
Anti-inflammatory action
Studied as an endogenous regulator of inflammatory response, with receptors on the immune cells that drive it.
Immune regulation
A modulating rather than stimulating role, which places it alongside Thymosin Alpha-1 rather than alongside a general immune supplement.
Pulmonary research
The bronchodilatory strand of the VIP literature, distinct from its immune work and a common reason people seek it out.
What the research does not show
The limits of the evidence, stated as plainly as the findings.
- Benefit in critical illness. The 2023 TESICO trial of IV aviptadil in COVID-19 respiratory failure found none.
Reconstitution and storage
The 5mg vial with 2 mL of bacteriostatic water gives 2.5mg/mL. VIP has a short half-life, and it is one of the peptides also researched by intranasal route for that reason; the vial we supply is lyophilised powder. Unopened vials are stable at room temperature in transit but belong in a fridge once they arrive, and out of a parked car in a Highveld summer.
Questions we get about VIP
Sources
- Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids, 2013.
- Souza-Moreira L, Delgado-Maroto V, et al. Potential applications of vasoactive intestinal Peptide-based therapies on transplantation. Endocrine, Metabolic & Immune Disorders Drug Targets, 2012.
- Brown SM, Barkauskas CE, et al. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. The Lancet. Respiratory Medicine, 2023.
Often bought with it
Order VIP in South Africa
Everything ships from Johannesburg, nationwide. Add it to your order slip, send the slip on WhatsApp, and we’ll confirm stock, pricing and delivery before you pay a cent.